Muscle tissue, in pink, is growing in each circular well. (Curi Bio Photo) Seattle-based startup Curi Bio has raised $10 million to advance its platforms for drug discovery, based on human stem cells.

SEATTLE, March 18, 2021 /PRNewswire/ -- Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced today it has raised $6 million in a Series A financing ...

Seattle, WA 98121 Phone: 800-913-4403 About Curi Bio Curi Bio provides a seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines.

Curi Bio, a leading developer of human iPSC-based platforms for drug discovery, has acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in ...

SEATTLE, November 22, 2024--(BUSINESS WIRE)--Curi Bio, a leader in delivering human functional data to drug discoverers through advanced preclinical tissue models, is proud to announce its ...

SEATTLE & PITTSBURGH, April 30, 2025--(BUSINESS WIRE)--Curi Bio, the global leader in human 3D engineered tissue platforms, and Cook MyoSite, a pioneer in the development of skeletal muscle-based ...

SEATTLE-- (BUSINESS WIRE)--#BioTech--Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of its Nautilus™ and Stingray™ platforms ...

NanoSurface Biomedical, a leading developer of human stem cell-based biotechnology products, today announced a comprehensive rebrand, including a change of the company’s name to Curi Bio.

Curi Bio Media Contact Heejoon Choi Sr. Director, Sales & Marketing [email protected] Cook MyoSite Media Contact Lindsy Bartoleit Senior Manager of Brand & Experience 412-923-6277 ...

Seattle, WA 98121 Phone: 800-913-4403 About Curi Bio Curi Bio provides a seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines.